Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $349.50 million. The enterprise value is $182.24 million.
Important Dates
The next confirmed earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 88.26 million shares outstanding. The number of shares has increased by 17.90% in one year.
| Current Share Class | 88.26M |
| Shares Outstanding | 88.26M |
| Shares Change (YoY) | +17.90% |
| Shares Change (QoQ) | +7.85% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 42.42% |
| Float | 87.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17,474.94 |
| Forward PS | n/a |
| PB Ratio | 2.09 |
| P/TBV Ratio | 2.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9,112.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.44, with a Debt / Equity ratio of 0.10.
| Current Ratio | 20.44 |
| Quick Ratio | 19.95 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -346.95 |
Financial Efficiency
Return on equity (ROE) is -55.91% and return on invested capital (ROIC) is -35.57%.
| Return on Equity (ROE) | -55.91% |
| Return on Assets (ROA) | -32.43% |
| Return on Invested Capital (ROIC) | -35.57% |
| Return on Capital Employed (ROCE) | -52.10% |
| Revenue Per Employee | $339 |
| Profits Per Employee | -$1.49M |
| Employee Count | 59 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -681,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.25% in the last 52 weeks. The beta is 0.06, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -41.25% |
| 50-Day Moving Average | 3.84 |
| 200-Day Moving Average | 4.94 |
| Relative Strength Index (RSI) | 50.26 |
| Average Volume (20 Days) | 2,754,915 |
Short Selling Information
The latest short interest is 21.50 million, so 24.36% of the outstanding shares have been sold short.
| Short Interest | 21.50M |
| Short Previous Month | 26.19M |
| Short % of Shares Out | 24.36% |
| Short % of Float | 24.55% |
| Short Ratio (days to cover) | 7.26 |
Income Statement
In the last 12 months, Altimmune had revenue of $20,000 and -$87.75 million in losses. Loss per share was -$1.17.
| Revenue | 20,000 |
| Gross Profit | -72.63M |
| Operating Income | -94.37M |
| Pretax Income | -88.43M |
| Net Income | -87.75M |
| EBITDA | -94.24M |
| EBIT | -94.37M |
| Loss Per Share | -$1.17 |
Full Income StatementBalance Sheet
The company has $183.11 million in cash and $15.85 million in debt, giving a net cash position of $167.26 million or $1.90 per share.
| Cash & Cash Equivalents | 183.11M |
| Total Debt | 15.85M |
| Net Cash | 167.26M |
| Net Cash Per Share | $1.90 |
| Equity (Book Value) | 161.37M |
| Book Value Per Share | 1.90 |
| Working Capital | 179.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.57 million and capital expenditures -$10,000, giving a free cash flow of -$81.58 million.
| Operating Cash Flow | -81.57M |
| Capital Expenditures | -10,000 |
| Free Cash Flow | -81.58M |
| FCF Per Share | -$0.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -471,850.00% |
| Pretax Margin | -442,135.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.90% |
| Shareholder Yield | -17.90% |
| Earnings Yield | -25.11% |
| FCF Yield | -23.34% |
Dividend DetailsAnalyst Forecast
The average price target for Altimmune is $16.50, which is 316.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.50 |
| Price Target Difference | 316.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 651.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 4.99 and a Piotroski F-Score of 2.
| Altman Z-Score | 4.99 |
| Piotroski F-Score | 2 |
